Literature DB >> 22314364

Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells.

Houbo Jiang1, Yong Ren, Eunice Y Yuen, Ping Zhong, Mahboobe Ghaedi, Zhixing Hu, Gissou Azabdaftari, Kazuhiro Nakaso, Zhen Yan, Jian Feng.   

Abstract

Parkinson's disease (PD) is defined by the degeneration of nigral dopaminergic (DA) neurons and can be caused by monogenic mutations of genes such as parkin. The lack of phenotype in parkin knockout mice suggests that human nigral DA neurons have unique vulnerabilities. Here we generate induced pluripotent stem cells from normal subjects and PD patients with parkin mutations. We demonstrate that loss of parkin in human midbrain DA neurons greatly increases the transcription of monoamine oxidases and oxidative stress, significantly reduces DA uptake and increases spontaneous DA release. Lentiviral expression of parkin, but not its PD-linked mutant, rescues these phenotypes. The results suggest that parkin controls dopamine utilization in human midbrain DA neurons by enhancing the precision of DA neurotransmission and suppressing dopamine oxidation. Thus, the study provides novel targets and a physiologically relevant screening platform for disease-modifying therapies of PD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22314364      PMCID: PMC3498452          DOI: 10.1038/ncomms1669

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  39 in total

1.  Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency.

Authors:  Bao-Yang Hu; Jason P Weick; Junying Yu; Li-Xiang Ma; Xiao-Qing Zhang; James A Thomson; Su-Chun Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-16       Impact factor: 11.205

Review 2.  Parkinson's disease. First of two parts.

Authors:  A E Lang; A M Lozano
Journal:  N Engl J Med       Date:  1998-10-08       Impact factor: 91.245

3.  Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism.

Authors:  T Kitada; S Asakawa; N Hattori; H Matsumine; Y Yamamura; S Minoshima; M Yokochi; Y Mizuno; N Shimizu
Journal:  Nature       Date:  1998-04-09       Impact factor: 49.962

4.  Parkin-deficient mice are not a robust model of parkinsonism.

Authors:  Francisco A Perez; Richard D Palmiter
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-31       Impact factor: 11.205

5.  The dopamine transporter carboxyl-terminal tail. Truncation/substitution mutants selectively confer high affinity dopamine uptake while attenuating recognition of the ligand binding domain.

Authors:  F J Lee; Z B Pristupa; B J Ciliax; A I Levey; H B Niznik
Journal:  J Biol Chem       Date:  1996-08-23       Impact factor: 5.157

6.  Parkin increases dopamine uptake by enhancing the cell surface expression of dopamine transporter.

Authors:  Houbo Jiang; Qian Jiang; Jian Feng
Journal:  J Biol Chem       Date:  2004-10-18       Impact factor: 5.157

Review 7.  Oxidative stress and the pathogenesis of Parkinson's disease.

Authors:  P Jenner; C W Olanow
Journal:  Neurology       Date:  1996-12       Impact factor: 9.910

8.  Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis.

Authors:  Houbo Jiang; Yong Ren; Jinghui Zhao; Jian Feng
Journal:  Hum Mol Genet       Date:  2004-06-15       Impact factor: 6.150

9.  Engrailed-1 as a target of the Wnt-1 signalling pathway in vertebrate midbrain development.

Authors:  P S Danielian; A P McMahon
Journal:  Nature       Date:  1996-09-26       Impact factor: 49.962

Review 10.  Monoamine oxidase: from genes to behavior.

Authors:  J C Shih; K Chen; M J Ridd
Journal:  Annu Rev Neurosci       Date:  1999       Impact factor: 12.449

View more
  114 in total

Review 1.  Redefining Parkinson's disease research using induced pluripotent stem cells.

Authors:  Jiali Pu; Houbo Jiang; Baorong Zhang; Jian Feng
Journal:  Curr Neurol Neurosci Rep       Date:  2012-08       Impact factor: 5.081

Review 2.  Induced pluripotent stem cells for modeling neurological disorders.

Authors:  Fabiele B Russo; Fernanda R Cugola; Isabella R Fernandes; Graciela C Pignatari; Patricia C B Beltrão-Braga
Journal:  World J Transplant       Date:  2015-12-24

Review 3.  Synaptic, Mitochondrial, and Lysosomal Dysfunction in Parkinson's Disease.

Authors:  Maria Nguyen; Yvette C Wong; Daniel Ysselstein; Alex Severino; Dimitri Krainc
Journal:  Trends Neurosci       Date:  2018-11-30       Impact factor: 13.837

Review 4.  Will brain cells derived from induced pluripotent stem cells or directly converted from somatic cells (iNs) be useful for schizophrenia research?

Authors:  Cheryl Filippich; Ernst J Wolvetang; Bryan J Mowry
Journal:  Schizophr Bull       Date:  2013-07-24       Impact factor: 9.306

5.  Comparative analysis of Parkinson's disease-associated genes in mice reveals altered survival and bioenergetics of Parkin-deficient dopamine neurons.

Authors:  Nicolas Giguère; Consiglia Pacelli; Caroline Saumure; Marie-Josée Bourque; Diana Matheoud; Daniel Levesque; Ruth S Slack; David S Park; Louis-Éric Trudeau
Journal:  J Biol Chem       Date:  2018-04-26       Impact factor: 5.157

Review 6.  Pluripotent stem cell-based therapy for Parkinson's disease: Current status and future prospects.

Authors:  Kai-C Sonntag; Bin Song; Nayeon Lee; Jin Hyuk Jung; Young Cha; Pierre Leblanc; Carolyn Neff; Sek Won Kong; Bob S Carter; Jeffrey Schweitzer; Kwang-Soo Kim
Journal:  Prog Neurobiol       Date:  2018-04-11       Impact factor: 11.685

7.  iPSC-derived dopamine neurons reveal differences between monozygotic twins discordant for Parkinson's disease.

Authors:  Chris M Woodard; Brian A Campos; Sheng-Han Kuo; Melissa J Nirenberg; Michael W Nestor; Matthew Zimmer; Eugene V Mosharov; David Sulzer; Hongyan Zhou; Daniel Paull; Lorraine Clark; Eric E Schadt; Sergio Pablo Sardi; Lee Rubin; Kevin Eggan; Mathew Brock; Scott Lipnick; Mahendra Rao; Stephen Chang; Aiqun Li; Scott A Noggle
Journal:  Cell Rep       Date:  2014-11-06       Impact factor: 9.423

Review 8.  Mimicking Parkinson's Disease in a Dish: Merits and Pitfalls of the Most Commonly used Dopaminergic In Vitro Models.

Authors:  Fernanda Martins Lopes; Ivi Juliana Bristot; Leonardo Lisbôa da Motta; Richard B Parsons; Fabio Klamt
Journal:  Neuromolecular Med       Date:  2017-07-18       Impact factor: 3.843

Review 9.  Cell replacement therapy is the remedial solution for treating Parkinson's disease.

Authors:  Venkatesan Dhivya; Vellingiri Balachandar
Journal:  Stem Cell Investig       Date:  2017-06-30

Review 10.  Using Patient-Derived Induced Pluripotent Stem Cells to Identify Parkinson's Disease-Relevant Phenotypes.

Authors:  S L Sison; S C Vermilyea; M E Emborg; A D Ebert
Journal:  Curr Neurol Neurosci Rep       Date:  2018-10-04       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.